- Home
- SKIL vs IPHA Comparison
SKIL vs IPHA Comparison
Compare SKIL & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIL
- IPHA
- Stock Information
- Founded
- SKIL 1998
- IPHA 1999
- Country
- SKIL United States
- IPHA France
- Employees
- SKIL N/A
- IPHA N/A
- Industry
- SKIL Computer Software: Prepackaged Software
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SKIL Technology
- IPHA Health Care
- Exchange
- SKIL Nasdaq
- IPHA Nasdaq
- Market Cap
- SKIL 136.7M
- IPHA 160.1M
- IPO Year
- SKIL N/A
- IPHA 2019
- Fundamental
- Price
- SKIL $15.75
- IPHA $1.74
- Analyst Decision
- SKIL
- IPHA Strong Buy
- Analyst Count
- SKIL 0
- IPHA 1
- Target Price
- SKIL N/A
- IPHA $11.00
- AVG Volume (30 Days)
- SKIL 79.1K
- IPHA 11.2K
- Earning Date
- SKIL 09-08-2025
- IPHA 09-11-2025
- Dividend Yield
- SKIL N/A
- IPHA N/A
- EPS Growth
- SKIL N/A
- IPHA N/A
- EPS
- SKIL N/A
- IPHA N/A
- Revenue
- SKIL $527,402,000.00
- IPHA $20,831,349.00
- Revenue This Year
- SKIL $3.18
- IPHA $209.83
- Revenue Next Year
- SKIL $2.50
- IPHA $83.15
- P/E Ratio
- SKIL N/A
- IPHA N/A
- Revenue Growth
- SKIL N/A
- IPHA N/A
- 52 Week Low
- SKIL $11.01
- IPHA $1.29
- 52 Week High
- SKIL $34.43
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SKIL 44.15
- IPHA 42.70
- Support Level
- SKIL $15.21
- IPHA $1.71
- Resistance Level
- SKIL $16.91
- IPHA $1.90
- Average True Range (ATR)
- SKIL 1.20
- IPHA 0.08
- MACD
- SKIL 0.15
- IPHA 0.00
- Stochastic Oscillator
- SKIL 60.13
- IPHA 47.62
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experience learner platform that serves learners world-wide. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.